(244 .tg/ml).
At the time of the peripheral thrombocytopenia aspiration of bone marrow showed increased numbers of megakaryocytes, and his serum was therefore investigated to detect the presence of an antibody against a pooled platelets/ sodium-valproate combination. On using both a complement fixation test at 37 C and a ['4C] serotonin platelet release technique' negative results were obtained at drug concentrations of 0-0065 g/l, 0-065 g/l, and 0-65 g/l. The antibody investigations were repeated 10 months after the thrombocytopenic episode and at a time when the patient's platelet count was within the normal range; negative results were again obtained. To 
Discussion
In a further 32 of our patients on sodium valproate, including several who were on large doses and had high serum levels of the drug, and five who also complained ofhair loss, no other cases ofhaemorrhage or platelet counts below 100 x 109/l were detected.
Apart from the sodium valproate with the very high serum level in our patient we found no other cause for the thrombocytopenia, which we therefore considered was probably due to the drug. The finding of increased numbers of megakaryocytes in the bone marrow, together with the rate ofplatelet recovery on discontinuing the drug, is suggestive of an immunological mechanism, though circulating platelet antibodies could not be detected in vitro. The negative results obtained during the thrombocytopenic phase may be explained by consumption of the antibody in vivo, though this mechanism cannot account for the negative findings in the recovery phase. A further possibility for the negative in-vitro results is that the circulating antibody is developed to a metabolic product of sodium valproate and not to the drug itself. It was considered unjustifiable to subject our patient to a further test dose of the drug, but it is of interest that in one of the previously reported cases of thrombocytopenia3 the platelet count recovered on stopping the sodium valproate but immediately fell on recommencing the drug.
As a result of these findings we recommend that any excessive or unexplained bruising or bleeding in a patient on sodium valproate is an indication for immediate platelet assessment. Parkinsonism with a bovine cough: an unusual presentation Limitation of coughing is a well-recognised feature of Parkinsonism usually seen late in the disease and predisposing the patient to chest infection and terminal bronchopneumonia. There appears to be no report of a patient with Parkinsonism having a bovine cough. This paper describes a patient in whom the first feature of Parkinsonism seems to have been a bovine cough, which preceeded the other features of the disease by about two years.
Case history
A 77-year-old man was first referred to the geriatric unit in July 1975 with poor mobility and increasing frailty. He had longstanding chronic bronchitis and bronchospasm, and was being treated with prednisilone, 10 mg thrice daily; salbutamol, 4 mg thrice daily; a combination tablet of amiloride, 5 mg, and hydrochlorothiazide, 50 mg, each morning; and promethazine, 50 mg, at night. In 1974 he had had two fractures of the right femur, which had resulted in 4-cm shortening of the leg. This physical disability and the severe dyspnoea from his chronic bronchitis were the causes of his poor mobility. Additionally, he had considerable asymptomatic prostatic enlargement, and a hoarse voice of low volume with a bovine cough. The only other neurological abnormality was a minor left upper motor neurone facial weakness. Both the patient and his wife confirmed that he had been unable to cough properly for about two years, and that this was slowly getting worse.
Both direct and indirect laryngoscopy failed to disclose any abnormality of the larynx, though an infraglottic tumour was suggested as possible cause of the bovine cough. Nevertheless, the results of barium swallow and tracheal tomography were normal. In view of his poor respiratory condition and general frailty further investigation was considered to be contraindicated. He regularly attended the geriatric day hospital, and at medical review in January 1976 was noticed to have developed a Parkinsonian tremor of the right hand; cogwheel rigidity in both arms; impassive facies, dyskinesia, and a positive glabellar tap. The bovine cough and feeble voice were still present. Treatment with a combination capsule of levodopa, 100 mg, and benserazide, 28-5 mg, was begun and the dose gradually increased to an optimum of one capsule thrice daily. As soon as he was first started on this treatment he began to produce normal explosive coughs; at first this occurred occasionally, but then, as the dose of the drug was increased, the bovine cough disappeared completely. At the same the volume of his voice increased. His other Parkinsonian features also improved, resulting in better mobility, reduction in rigidity, and disappearance of dyskinesia.
